**FENOC**™
*FirstEnergy Nuclear Operating Company*

*Beaver Valley Power Station*
*P.O. Box 4*
*Shippingport, PA 15077*

***Eric A. Larson***
*Site Vice President*

*724-682-5234*
*Fax: 724-643-8069*

August 12, 2013
L-13-273

10 CFR 26.719(c)

ATTN: Document Control Desk
U. S. Nuclear Regulatory Commission
Washington, DC 20555-0001

SUBJECT:
Beaver Valley Power Station, Unit Nos. 1 and 2
BV-1 Docket No. 50-334, License No. DPR-66
BV-2 Docket No. 50-412, License No. NPF-73
Submittal of 30-Day Report per 10 CFR 26.719(c), "Drug and Alcohol Testing Errors"

In accordance with 10 CFR 26.719(c), "Drug and alcohol testing errors," FirstEnergy Nuclear Operating Company (FENOC) is providing the attached fitness-for-duty incident report.

As required, this report is being submitted within 30 days of completing an investigation of any testing errors or unsatisfactory performance discovered in performance testing at either a licensee testing facility or a Health and Human Services (HHS)-certified laboratory, in the testing of quality control or actual specimens. The investigation associated with this incident was completed July 13, 2013; therefore, this report is due by August 12, 2013. This report includes a description of the incident and corrective actions taken.

There are no regulatory commitments contained in this letter. Should you have any questions or additional information is required, please contact Mr. Brian F. Sepelak, Supervisor, Regulatory Compliance, at (724) 682-4282.

Sincerely,

Eric A. Larson

Attachment: Fitness-for-Duty Incident Report - 10 CFR 26.719(c)

cc: Mr. W. M. Dean, NRC Region I Administrator
Mr. D. I. Spindler, NRC Senior Resident Inspector
Mr. P. J. Bamford, NRR Project Manager

A021
NRR

ATTACHMENT
L-13-273

30-Day Report per 10 CFR 26.719(c), "Drug and Alcohol Testing Errors"


Description of the Incident

On May 15, 2013, in accordance with 10 CFR 26.168 "Blind performance testing," FirstEnergy Nuclear Operating Company (FENOC) forwarded a blind performance specimen, acquired from ElSohly Laboratory certified as adulterated with nitrites at a concentration of 840 mcg/ml, to HHS-certified MedTox Laboratory for testing as a pre-access urine specimen, Custody and Control Form (CCF) specimen I.D.: Z24303358. MedTox received the specimen on May 16, 2013.

On May 22, 2013, MedTox reported that the specimen was "invalid" and quantified the nitrites at a level of 380 mcg/ml based on the confirmatory test. This result was inconsistent with the expected adulterated finding of a measured level over 500 mcg/ml. FENOC contacted MedTox on May 24, 2013 to inquire further as to the finding. The FENOC Medical Review Officer (MRO) was informed that two screening results had measured a level over 500 mcg/ml; however, confirmation testing resulted in a level below the 500 mcg/ml threshold of adulteration. MedTox suggested that this was possibly due to the presence of other oxidants such as chromium.

On May 24, 2013, FENOC requested MedTox to forward the split specimen to ElSohly for testing and verification of nitrite level. On May 29, 2013, notification was received that ElSohly was unable to perform the quantitative analysis for nitrites and recommended that the specimen be forwarded to an HHS-certified laboratory, Quest Diagnostics Laboratory in Atlanta, for the requested testing. On May 29, 2013, FENOC requested ElSohly to forward the specimen to Quest Diagnostics Laboratories for a quantitative analysis of nitrites.

On June 11, 2013, Quest Diagnostics Laboratories reported the specimen as being "adulterated" with a Nitrite level of 687 mcg/ml to FENOC by amended report for CCF specimen I.D.: Z24303358. Based on this independently confirmed result, FENOC determined that the May 22, 2013 MedTox report of an "invalid" specimen was incorrect, the specimen should have reported as "adulterated." On June 12, 2013, FENOC advised MedTox of the issue and entered the issue into the FENOC corrective action program (CR-2013-09103).

Investigation

On June 13, 2013, FENOC Oversight issued a Supplier Action Request 2013-0105-01 to MedTox which requested an investigation including cause, extent of condition and corrective actions. The MedTox response dated July 13, 2013 determined that the error in the original confirmation test was random in nature in that there was no apparent deviation from expected performance of the equipment and the testing was performed by an experienced analyst. The MedTox Certifying Scientist is responsible for reviewing the results and resolving any inconsistencies. In this case, the MedTox Certifying

Scientist failed to adequately investigate and resolve the inconsistency between the screening and confirmatory test results. This resulted in the incorrect "invalid" specimen result being reported to FENOC. MedTox concluded the that error was an isolated case and no systematic issues were identified.

Corrective Actions

MedTox has taken the following corrective actions: 1) the appropriate procedure for utilization and comparison of initial screening and confirmation data and corrective action for discrepant results has been reviewed with the Certifying Scientist, 2) each MedTox Certifying Scientist has completed additional training, and 3) the MedTox standard operating procedure for Analysis of Nitrite in Urine has been revised to be more rigorous in the comparison of the initial and confirmatory results prior to reporting.

Conclusion

FENOC has reviewed the MedTox response and the corrective measures taken by MedTox are considered satisfactory to address this issue. FENOC will continue to monitor MedTox performance.